ReviewClinical cardiology2021
Cardiac amyloidosis-A review of current literature for the practicing physician.
Review in Clinical cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Machine learning-based methods in diagnosing cardiac amyloidosis: a meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.ESC heart failure · 2022Pooled it
- Abdominal manifestations of multisystem diseases: a pattern-based imaging review.Abdominal radiology (New York) · 2026Review
- Multimodality Imaging in Cardiac Amyloidosis.Journal of clinical medicine · 2025Review
- Development and validation of an echocardiographic nomogram for identifying cardiac amyloidosis in patients with left ventricular hypertrophy.BMC cardiovascular disorders · 2025Article
- A Dose-Tailored Anti-Plasma Cell Regimen Lowers the Mortality of Late-Stage Cardiac Amyloidosis.MedComm · 2025Article
- Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.The international journal of cardiovascular imaging · 2025Review
- Associations between pathophysiological traits and symptom development in retrospective analysis of V30M and V122I transthyretin amyloidosis.International journal of cardiology. Heart & vasculature · 2025Article
- A case series of patients with cardiac amyloidosis evaluated at a Colombian university hospital.Frontiers in cardiovascular medicine · 2025Article
- First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia.ESC heart failure · 2024Article
- Histopathological and Immunohistochemical Characteristics of Different Types of Cardiac Amyloidosis.International journal of molecular sciences · 2024Observational
- Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review.Cardiology research · 2024Review
- Article
- Article
- Examining the Difficulties in Identifying and Handling Cardiac Amyloidosis; Acquiring Important Knowledge and Robust Treatment Methods.Cardiovascular & hematological disorders drug targets · 2024Review
- Advance of echocardiography in cardiac amyloidosis.Heart failure reviews · 2023Review
- Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Article
- 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis.Acta Cardiologica Sinica · 2023Article
- Systemic AL amyloidosis: current approach and future direction.Oncotarget · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The amyloidoses are a family of diseases in which misfolded precursor proteins aggregate to form amyloid and deposit in body tissues. A very serious yet underrecognized form of this disease is cardiac amyloidosis, in which amyloid deposits into the extracellular space of the myocardium, resulting in thickening and stiffening of ventricular walls with resultant heart failure and conductive dysfunction. This review provides a discussion of the pathogenesis and clinical presentation of cardiac amyloidosis subtypes, as well as an up-to-date approach to diagnosis and treatment. Significant progress has been made in recent years regarding diagnosis and treatment of this condition, but prognosis remains heavily reliant on early detection of the disease. Two types of precursor protein are responsible for most cardiac amyloidosis cases: transthyretin amyloid, and immunoglobulin-derived light chain amyloid. An early diagnosis of cardiac amyloidosis can allow for novel treatment modalities to be initiated with the potential to improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.